Höpfner M - Search Results

1

In-ovo echocardiography for application in cardiovascular research.

Hegemann N, Bintig W, Perret PL, Rees J, Viperino A, Eickholt B, Kuebler WM, Höpfner M, Nitzsche B, Grune J. Hegemann N, et al. Among authors: hopfner m. Basic Res Cardiol. 2023 May 16;118(1):19. doi: 10.1007/s00395-023-00989-0. Basic Res Cardiol. 2023. PMID: 37193927 Free PMC article.

2

Antitumor activity of the new tyrphostin briva against BRAF^V600E-mutant colorectal carcinoma cells.

Saleh K, Al Sakhen M, Kanaan S, Yasin S, Höpfner M, Tahtamouni L, Biersack B. Saleh K, et al. Among authors: hopfner m. Invest New Drugs. 2023 Dec;41(6):791-801. doi: 10.1007/s10637-023-01402-2. Epub 2023 Oct 23. Invest New Drugs. 2023. PMID: 37870738

3

Synthetic Small Molecule Modulators of Hsp70 and Hsp40 Chaperones as Promising Anticancer Agents.

Nitzsche B, Höpfner M, Biersack B. Nitzsche B, et al. Among authors: hopfner m. Int J Mol Sci. 2023 Feb 17;24(4):4083. doi: 10.3390/ijms24044083. Int J Mol Sci. 2023. PMID: 36835501 Free PMC article. Review.

4

Synthesis and Anticancer Evaluation of New Indole-Based Tyrphostin Derivatives and Their (p-Cymene)dichloridoruthenium(II) Complexes.

Oberhuber N, Ghosh H, Nitzsche B, Dandawate P, Höpfner M, Schobert R, Biersack B. Oberhuber N, et al. Among authors: hopfner m. Int J Mol Sci. 2023 Jan 3;24(1):854. doi: 10.3390/ijms24010854. Int J Mol Sci. 2023. PMID: 36614289 Free PMC article.

5

New chimeric HDAC inhibitors for the treatment of colorectal cancer.

Bär SI, Pradhan R, Biersack B, Nitzsche B, Höpfner M, Schobert R. Bär SI, et al. Among authors: hopfner m. Arch Pharm (Weinheim). 2023 Feb;356(2):e2200422. doi: 10.1002/ardp.202200422. Epub 2022 Nov 28. Arch Pharm (Weinheim). 2023. PMID: 36442846

6

Editorial: Advances in molecular targeted therapies of urologic cancers.

Nitzsche B, Höpfner M. Nitzsche B, et al. Among authors: hopfner m. Front Oncol. 2022 Oct 19;12:1062015. doi: 10.3389/fonc.2022.1062015. eCollection 2022. Front Oncol. 2022. PMID: 36338677 Free PMC article. No abstract available.

7

Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimization.

Biersack B, Nitzsche B, Höpfner M. Biersack B, et al. Among authors: hopfner m. Semin Cell Dev Biol. 2024 Feb 15;154(Pt C):286-294. doi: 10.1016/j.semcdb.2022.09.009. Epub 2022 Sep 18. Semin Cell Dev Biol. 2024. PMID: 36127263 Review.

8

Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma.

Ma A, Biersack B, Goehringer N, Nitzsche B, Höpfner M. Ma A, et al. Among authors: hopfner m. J Pers Med. 2022 May 1;12(5):738. doi: 10.3390/jpm12050738. J Pers Med. 2022. PMID: 35629160 Free PMC article.

9

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer.

Biersack B, Nitzsche B, Höpfner M. Biersack B, et al. Among authors: hopfner m. Cancer Drug Resist. 2022 Jan 4;5(1):64-79. doi: 10.20517/cdr.2021.105. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35582529 Free PMC article. Review.

10

Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer.

Bär SI, Dittmer A, Nitzsche B, Ter-Avetisyan G, Fähling M, Klefenz A, Kaps L, Biersack B, Schobert R, Höpfner M. Bär SI, et al. Among authors: hopfner m. Int J Oncol. 2022 Jun;60(6):73. doi: 10.3892/ijo.2022.5363. Epub 2022 Apr 29. Int J Oncol. 2022. PMID: 35485292 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

107 results

Search Page